The hepatitis B vaccine, once a significant triumph in public health, is now facing intense scrutiny as Robert F. Kennedy Jr. and a federal panel contemplate delaying its administration to newborns. Concerns have been raised by health officials and scientists who warn that such changes could jeopardize child health, arguing that the vaccine has substantially reduced infections. Meanwhile, debates continue over the necessity of this vaccine for infants, with varied opinions emerging from the CDC and FDA on its importance. As discussions progress, the implications for health policy and childhood immunization remain uncertain.